Press Releases

 
Press Releases
Date Title and Summary View
Aug 17, 2017 SALT LAKE CITY, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Palmetto GBA, the Medicare contractor who oversees the MolDx program and Anthem, Inc., one of the largest private insurers in the country, have announced po...
Aug 8, 2017 Total Revenues of $200.5 Million Up 8 PercentGAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term ContractCompany Issues Fiscal Year 2018 and Fiscal First-Quarter 2018...
Jul 28, 2017 SALT LAKE CITY, July 28, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 8, 2017.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, ...
Jun 19, 2017 SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, to...
Jun 15, 2017 SALT LAKE CITY, June 15, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra® DA test to predict joint damage were presented at the European...
Jun 8, 2017 SALT LAKE CITY, June 08, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) meeting being held June 14-17, 2017, in Mad...
Jun 4, 2017 SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Jun 2, 2017 SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana, Inc., and multiple regiona...
Jun 2, 2017 SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced re...
May 31, 2017 SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicag...
Page:
1
... NextLast
= add release to Briefcase